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Abstract 
Background: Mycobacterium tuberculosis multidrug resistance, especially against rifampicin and isoniazid, places pul-
monary tuberculosis in the list of emerging diseases. The misuse of therapeutic regimens is one of its main predispos-
ing factors.
Case presentation: Four clinical cases (three were brown and one black) with multidrug-resistant tuberculosis, 
treated in a reference hospital in the state of Maranhão, Brazil, were reported to evaluate the importance of radiologi-
cal framework on disease evolution.
Conclusion: The clinical framework showed a bad evolution and drug resistance, while radiology showed lung 
lesions, ranging from exudative infiltrates to lung parenchyma disintegration.
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Background
The adverse effects of anti-tuberculosis drugs are related 
to the high incidence of noncompliance to treatment [1]. 
Bacillus’ resistance to anti-tuberculosis drugs is related 
to wild strain mutations and the mutant selection pro-
cess during treatment [2–4] in cases related to discon-
tinuation or irregular treatment with standard regimens. 
Cases that led to primary resistance or acquired resist-
ance, without contact, have also been found upon using 
specific drugs [5]. Cavitary tuberculosis cause outbreaks 
with higher resistance and mutant frequency [2].
This paper shows four clinical cases of patients with 
multidrug-resistant tuberculosis (MDR-TB) assisted in 
a reference hospital in the state of Maranhão, Brazil. In 
addition, the radiological framework importance on dis-
ease evolution was assessed.
Case presentation
This paper consists of a retrospective study with 41 con-
firmed MDR-TB cases in 2003–2010. Only four cases are 
described in this series, as they had a complete support-
ing documentation.
Case 1
A 33-year-old man, brown, married, was admitted in 
October 2006, with a history of Scheme III failure (indi-
cated for therapeutic failure; 2  months with streptomy-
cin, ethionamide, ethambutol and pyrazinamide, and 
4 months with ethionamide and ethambutol) and resist-
ance to rifampicin, isoniazid and streptomycin; negative 
HIV test; chest radiograph showed a right hemithorax 
fissure rectification and an exudative bronchiectasis 
lesion in the hemithorax. One  year and 1  month later, 
fibro-atelectatic lesions were observed in the right upper 
lobe. The patient initiated the MDR-TB treatment 3 years 
later, having a positive sputum smear for acid-fast bacilli 
(AFB), confirmed by culture, with an oscillating pattern, 
and two positive cultures for Mycobacterium tuberculo-
sis, with resistance to isoniazid, rifampicin, streptomycin 
and ethambutol. MR scheme for MR-X was conducted 
with ciprofloxacin, clarithromycin and pyrazinamide. 
Terizidone and bacilloscopies continued with an oscillat-
ing pattern. During 2 years and 6 months, two negative 
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cultures were performed, with clinical resolution and 
radiological pattern of healing (Table 1).
Case 2
A 27-year-old woman, brown, single, student, with a 
history of irregular treatment with regimen I in 2005 
(indicated for new pulmonary and extra-pulmonary 
tuberculosis cases, except tuberculous meningitis; 
2 months with rifampicin, isoniazid and ethambutol, and 
4 months with rifampicin and isoniazid). HIV was nega-
tive. After 6  months, the patient developed productive 
cough, fatigue, fever episodes and gastrointestinal symp-
toms, then resumed with the tuberculostatic medica-
tion. The radiological framework showed residual pleural 
injury. Three years later, a cavitary lesion in the left upper 
lobe and bilaterally diffuse alveolar infiltrates were found 
when the enhanced scheme I was repeated, as having a 
positive sputum smear for AFB. A month later, bilat-
eral lesions were found with cavities in the right upper 
lobe, positive smear and culture, and then the MDR-TB 
treatment began. Three months later, the positive cul-
ture remained, and a bilateral parenchymal fibrosis to 
the right was observed. A month later, the radiological 
examination showed bilaterally diffuse interstitial-alveo-
lar infiltrate. Two months later, the radiological examina-
tion showed alveolar lesions in the apices, an atelectasis 
band to the right and a positive culture. Four years later, 
decreased lung size, atelectasis bands and cavitary lesions 
in the upper lobes were found. Three months later, bilat-
eral bronchiectasis areas were observed. After three 
months, the patient was in a severe general condition. 
Five years later, a positive smear was found and an alter-
native scheme began. A month later, bilateral cavitation 
areas were observed, with right lung reduction. Three 
months later, radiological pattern persisted and posi-
tive smear with sensitivity tests indicating isoniazid and 
rifampicin resistance were found. Although the patient 
was treated, the severity evolved without improvement 
and the patient died 2 months later (Table 1).
Case 3
A 38-year-old woman, black, homemaker. Chest radiog-
raphy showed diffuse interstitial-alveolar infiltrates with 
pulmonary parenchyma, bubbles and bronchiectasis in 
the upper lobes. The treatment with scheme I began in 
2006. It was abandoned, and the patient resumed treat-
ment 1 year later with an enhanced scheme I. After a few 
months, the patient stopped taking medication, and the 
treatment resumed with the MDR-TB regimen. Three 
months later, being the smear positive, a positive cul-
ture for M. tuberculosis was observed in the susceptibil-
ity test, showing resistance to isoniazid and rifampicin. 
Six months later, Mycobacterium hodleri was identified 
by PCR. Seven months later, a radiograph showed large 
pneumatoceles in the upper lobes, left apical bronchiec-
tasis, and fibro-exudative and cavitary lesions in the upper 
segments of lower lobes. Three months later, the patient 
was discharged after the cure of MDR-TB, returning 
repeatedly for 10 months, when the AFB smear was posi-
tive. Chest radiograph showed bubbles, bronchiectasis 
and fibrous residual lesions in the upper lobes (Table 1).
Case 4
An 18-year-old woman, brown, single, peasant. She 
started the regimen I treatment in 2003, and abandoned 
it. One year later, the treatment was resumed with the 
enhanced scheme I, showing therapeutic failure. One 
year later, the MDR-TB treatment began. Two years later, 
the patient was treated for MDR-X tuberculosis. Bacil-
loscopy oscillated during the course of treatment. The 
culture trials conducted during treatment were positive 
for M. tuberculosis, showing a resistance to isoniazid, 
rifampicin and ethambutol. Six months later, a chest radi-
ograph showed alveolar infiltrates in the left lung base. A 
year and 10 months later, the radiograph showed left lung 
parenchymal destruction, with cavitary lesions in the 
right upper lobe (Table 1).
Discussion
Although the literature describes a high toxicity of drugs 
used in the MDR-TB treatment [6], adverse effects were 
only observed in one case (25 %).
Through the report of four cases, the presence of severe 
pulmonary lesions with irreversible characteristics was 
radiographically evident, usually beginning with exuda-
tive lesions and parenchymal lung destruction. Case 3 
shows a concomitant infection by M. hodleri, with very 
exuberant lung lesions. All patients described abandoned 
treatment, and had cavitary and fibro residual lesions and 
treatment failure, and showed no HIV coinfection, which 
is an association commonly described in the literature 
[7].
Chest radiography predicts tuberculosis prognosis by 
evaluating pulmonary lesions [7], and it is still the most 
used imaging method [8]. Cavitary lesions and residual 
fibrosis found related to multidrug resistance corroborate 
the literature [2].
In this study, 7.3 % of MDR-TB and 2.4 % of XDR were 
found, values lower than those reported for the USA. 
Marks et al. [9] found a prevalence of 36 % of MDR-TB 
and 56 % of XDR-TB in 2005–2007 [9]. Regarding drugs, 
resistance to rifampicin and isoniazid, as well as age 
(young adults), supported the findings of a study con-
ducted in Congo [10].
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In summary, MDR-TB is a major public health problem 
in Brazil, especially in poor areas such as the Brazilian 
North and Northeast.
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Table 1 Clinical characteristics of  patients with  docu-
mented multidrug-resistant tuberculosis (MDR-TB)
CXR chest radiograph, Eth ethambutol, INH isoniazid, Rif rifampin, Stm 
streptomycin, GI gastrointestinal
a Patients were tested for resistance to Eth, INH, Rif, PZA, Stm, Km, Cm, and Tha, 
as well as resistance to ciprofloxacin and cycloserine






























2 27 5 INH, Rif Yes – GI
3 38 4 INH, Rif Yes – None
4 18 7 INH, Rif, 
Eth
Yes – None
